SEC Form 4 · accession 0001140361-15-011502

Coherus Oncology, Inc. · CHRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President & CEO · Director

Period of report

Mar 10, 2015

Accepted (ET)

Mar 12, 2015 · 4:18 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001512762

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.0001 par value^F2	Mar 10, 2015	J	799	$0.00	A	1,342,720	I	By Trust
Common Stock, $0.0001 par value	Mar 10, 2015	J	828	$0.00	A	69,551	D
Common Stock, $0.0001 par value^F3	Mar 10, 2015	J	4	$0.00	A	86,952	I	By LLC

No Table II lines on this filing.

F1On March 10, 2015, Reporting Person and Reporting Person's Trust and Limited Liability Company became entitled to receive shares of Issuer's common stock pursuant to the release of shares from escrow pursuant to the terms and conditions of that certain Agreement and Plan of Merger by and among Issuer, Coherus Intermediate Corp., Coherus Acquisition Corp., InteKrin Therapeutics Inc. ("InteKrin") and Fortis Advisors LLC, dated as of January 8, 2014 ("Merger Agreement"), pursuant to which Issuer acquired InteKrin. The shares issued to Reporting Person had been held in escrow for satisfaction to the indemnification obligations of the former stockholders of InteKrin to Issuer. The release of the shares issued to Reporting Person by the escrow agent was executed on March 10, 2015 upon determination by the escrow agent under the Merger Agreement, stockholders' representative under the Merger Agreement and transfer agent to Issuer that all conditions for such release had been satisfied.
F2These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
F3These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.